Breast Cancer

The Pharmacy Times® Breast Cancer resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.

What can we help you find?
[[thumbnail_alt_text]]
Approximately 30% of women gain weight following chemotherapy for breast cancer, gut bacteria may be why. 
 
[[thumbnail_alt_text]]
FDA approves FoundationOne Liquid CDx as a companion diagnostic for alpelisib in advanced or metastatic breast cancer, rucaparib in advanced ovarian cancer, and alectinib in a specific type of metastatic non–small cell lung cancer.
[[thumbnail_alt_text]]
An axillary lymph node dissection, which is the surgical removal of 10 to 20 lymph nodes from the breast, is a procedure conducted in up to 25% of women with breast cancer to disable symptoms of arm swelling.
[[thumbnail_alt_text]]
Lipid-lowering medication may be an effective adjuvant cancer therapy. 
 
[[thumbnail_alt_text]]
Women diagnosed with cancer as adolescents or young adults can be especially vulnerable to the impact of the disease and its treatment on their ability to work.
[[thumbnail_alt_text]]
The authors concluded that a single dose of targeted intraoperative radiotherapy should be an option accessible to health care providers and discussed with patients.
 
[[thumbnail_alt_text]]
Study findings align with recent recommendations from the National Comprehensive Cancer Network for preventing febrile neutropenia in patients with early-stage breast cancer.
[[thumbnail_alt_text]]
Patients should talk to their health care team about when to reschedule a postponed or cancelled screening appointment.
[[thumbnail_alt_text]]
Lenvatinib (Lenvima) plus pembrolizumab (Keytruda) showed early antitumor activity and tolerability in previously treated triple-negative breast cancer patients with advanced solid tumors.
[[thumbnail_alt_text]]
Trial shows that olaparib, a poly ADP ribose polymerase inhibitor that is the first cancer drug to target an inherited genetic fault, can be used successfully to treat prostate cancers with a weakness in the ability to repair damaged DNA.
[[thumbnail_alt_text]]
Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer.
[[thumbnail_alt_text]]
Study shows the recurrence rate was within the expected range for breast cancer survivors receiving spironolactone and those who did not.